myeloma, from about 1 mg to about 5 mg per day of a compound having the formula:



or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein the compound is administered in one or more cycles, each of which comprises administering the compound for a period of time followed by a period of rest, wherein the multiple myeloma is relapsed, refractory, or relapsed and refractory multiple myeloma.

2. The method of claim **1**, wherein the patient has demonstrated disease progression on the previous therapy.

3. The method of claim **1**, wherein the previous therapy is treatment with thalidomide, a proteasome inhibitor, or a combination thereof.

4. The method of claim **1**, wherein the previous therapy is treatment with stem cell transplantation.

5. The method of claim **2**, wherein the previous therapy is treatment with a proteasome inhibitor.

6. The method of claim **1**, wherein the patient is 65 years or younger.

7. The method of claim **1**, wherein the patient is older than 65 years.

8. The method of claim **1**, wherein the compound is administered in an amount of about 4 mg per day.

9. The method of claim **1**, wherein the compound is administered in an amount of about 3 mg per day.

10. The method of claim **1**, wherein the compound is administered in an amount of about 2 mg per day.

11. The method of claim **1**, wherein the compound is administered in an amount of about 1 mg per day.

12. The method of claim **1**, wherein the compound is administered as a free base.

13. The method of claim **1**, wherein the compound is administered orally.

14. The method of claim **1**, wherein the compound is administered in a capsule.

15. The method of claim **1**, wherein the compound is administered in a tablet.

16. The method of claim **14**, wherein the capsule comprises the compound, mannitol and pre-gelatinized starch.

17. The method of claim **1**, wherein the compound is administered orally in a capsule of 1 mg, 2 mg, 3 mg, or 4 mg.

18. The method of claim **1**, wherein one cycle comprises four to six weeks.

19. The method of claim **1**, wherein the compound is administered for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle.

20. The method of claim **1**, wherein the compound is orally administered 4 mg per day on days 1 through 21 of repeated 28-day cycles until disease progression.

21. The method of claim **1**, which further comprises administering a therapeutically effective amount of an additional active agent.

22. The method of claim **21**, wherein the additional active agent is dexamethasone.

23. The method of claim **22**, wherein 40 mg dexamethasone is administered.

24. The method of claim **22**, wherein the dexamethasone is orally administered once daily on days 1, 8, 15 and 22 of a 28 day cycle.

25. The method of claim **22**, wherein the dexamethasone is orally administered once a week of a 28 day cycle.

26. A method of treating multiple myeloma, which comprises administering to a patient having multiple myeloma, and which patient has received previous therapy for multiple myeloma and has demonstrated disease progression on the previous therapy, from about 1 mg to about 5 mg per day of a compound having the formula:



or a solvate thereof, wherein the compound is administered in one or more cycles, each of which comprises administering the compound for a period of time followed by a period of rest.

27. The method of claim **26**, wherein the previous therapy is treatment with a proteasome inhibitor.

28. The method of claim **26**, wherein the compound is administered in an amount of about 4 mg, 3 mg, 2 mg or 1 mg per day.

29. The method of claim **26**, wherein the compound is administered as a free base.

30. The method of claim **26**, wherein the compound is administered orally.

31. The method of claim **26**, wherein the compound is administered in a capsule.

32. The method claim **26**, wherein the compound is administered for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle.

33. The method of claim **26**, which further comprises administering a therapeutically effective amount of dexamethasone.

34. The method of claim **33**, wherein 40 mg dexamethasone is administered.

35. The method of claim **33**, wherein the dexamethasone is orally administered once daily on days 1, 8, 15 and 22 of a 28 day cycle.

* * * * *